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a  b  s  t  r  a  c  t
Background: Testosterone deﬁciency (hypogonadism) is common among men undergoing
haemodialysis, but its clinical implications are not well characterized. Testosterone is an
anabolic hormone that induces erythrocytosis and muscle synthesis. We hypothesized that
testosterone deﬁciency would be associated with low muscle mass, physical inactivity and
higher dosages of erythropoietin-stimulating agents (ESA).
Methods: Single-center cross-sectional study of 57 male haemodialysis patients. None of
the  patients was undergoing testosterone replacement therapy. Total testosterone was mea-
sured in serum. Body composition (by bioelectrical impedance analysis) and physical activity
(by  the use of pedometers) were assessed. Patients with testosterone levels below the normal
range were considered hypogonadal.
Results: Mean testosterone level was 321 ± 146 ng/dL; 20 patients (35%) were hypogonadal.
Hypogonadal patients were older and had lower mean arterial blood pressure, higher
interleukin-6 levels, lower lean body mass and higher fat body mass. A negative associa-
tion between testosterone and normalized ESA dose was found in uni- and multivariate
regression analyses. Testosterone levels directly correlated with lean body mass regardless
of  confounders. Hypogonadal patients had lower physical activity than their counterparts
[2753 ± 1784 vs. 4291 ± 3225 steps/day (p = 0.04)]. The relationship between testosterone andPlease cite this article in press as: Cobo G, et al. Hypogonadism associated with muscle atrophy, physical inactivity and ESA hyporesponsiveness
in men undergoing haemodialysis. Nefrologia. 2016. http://dx.doi.org/10.1016/j.nefro.2016.04.009
physical activity was independent of age, comorbidities and inﬂammatory markers, but
dependent on the proportion of muscle mass.
Conclusion: Hypogonadism is common in our male haemodialysis population and is asso-
ciated with higher ESA doses, reduced muscle mass and lower physical activity. The link
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between low testosterone levels and physical inactivity may conceivably relate to reduced
muscle  mass due to inadequate muscle protein synthesis.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Hipogonadismo  asociado  a  atroﬁa  muscular,  inactividad  física  e





r  e  s  u  m  e  n
Antecedentes: La deﬁciencia de testosterona (hipogonadismo) es frecuente en varones en
hemodiálisis, pero sus consecuencias clínicas no se han caracterizado satisfactoriamente.
La  testosterona es una hormona anabólica que provoca eritrocitosis y síntesis muscular.
Nos  planteamos la hipótesis de que la deﬁciencia de testosterona pudiera estar asociada a
una  masa muscular baja, a la inactividad física y a dosis más altas de fármacos estimulantes
de  la eritropoyesis (FEE).
Métodos: Estudio transversal de un solo centro de 57 pacientes varones en hemodiálisis.
Ninguno de ellos estaba recibiendo tratamiento sustitutivo con testosterona. La cantidad
total de testosterona se midió en el suero. Se evaluaron la composición corporal (mediante
un análisis de impedancia bioeléctrica) y la actividad física (mediante el uso de podómet-
ros).  Los pacientes con concentraciones séricas de testosterona por debajo de los límites de
normalidad se consideraron hipogonadales.
Resultados: La concentración media de testosterona fue de 321 ± 146 ng/dl; 20 pacientes (35%)
se  consideraron hipogonadales. Los pacientes hipogonadales eran de edad avanzada y pre-
sentaban una presión arterial media más baja, concentraciones más altas de interleucina
6,  masa corporal magra más baja y masa corporal grasa más  alta. Se observó una aso-
ciación negativa entre la dosis de testosterona y de FEE normalizada en análisis de regresión
univariante y multivariante. Las concentraciones de testosterona estaban directamente cor-
relacionadas con la masa corporal magra, independientemente de los factores de confusión.
Los  pacientes hipogonadales presentaban una actividad física más  baja que sus homólogos
(2.753 ± 1.784 frente a 4.291 ± 3.225 pasos/día; p = 0,04). La relación entre la actividad física
y  la testosterona fue independiente de la edad, las comorbilidades y los marcadores de
inﬂamación, pero dependían de la proporción de masa muscular.
Conclusión: El hipogonadismo es frecuente en la población de varones en hemodiálisis y está
asociado a dosis más altas de FEE, masa muscular reducida y actividad física baja. El vínculo
entre  las concentraciones bajas de testosterona y la inactividad física está posiblemente
relacionado con la masa muscular reducida debido a una síntesis de proteínas musculares
insuﬁciente.
© 2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/Introduction
Chronic kidney disease (CKD) involves alterations in body
homeostasis and metabolic disturbances (including hormone
secretion disorders and altered response to hormones in tar-
get tissues), resulting in endocrine dysfunctions that may
contribute to the increased mortality in CKD patients.1 Hypog-
onadism, hallmarked by testosterone deﬁciency is a common
endocrine disorder among men  undergoing dialysis, with a
prevalence ranging from 35 to 50% in recent studies.2–4 Var-
ious studies link hypogonadism with mortality risk among
hemodialysis patients,5,6 but the pathways by which this riskPlease cite this article in press as: Cobo G, et al. Hypogonadism associated w
in men undergoing haemodialysis. Nefrologia. 2016. http://dx.doi.org/10.1
may be mediated are not well known.
The clinical implications of hypogonadism among dialysis
patients are not well characterized. Testosterone is a steroidby-nc-nd/4.0/).
hormone that has an important anabolic function inﬂuenc-
ing among others muscle mass, increasing both strength
and size.7 In the general population, testosterone deﬁciency
that accompanies aging has been linked to decreased phys-
ical performance and its consequent limitation of mobility.8
In non-dialysis CKD patients, endogenous testosterone is a
strong determinant of both muscle mass and strength.9 It is
unknown if this is still the case in individuals undergoing
dialysis.
Furthermore, testosterone induces erythrocytosis10,11 and
testosterone deﬁciency has been associated with anemia
and increased resistance to erythropoietin-stimulating agents
(ESA) in dialysis patients.2 However, this ﬁnding has, to date,ith muscle atrophy, physical inactivity and ESA hyporesponsiveness
016/j.nefro.2016.04.009
not been conﬁrmed. The objective of our study was to assess
the prevalence of hypogonadism among men  undergoing dial-
ysis at our center. Further, we  explored the clinical phenotype
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f hypogonadal patients. Based on the abovementioned
receding literature, we  hypothesized that endogenous testos-
erone would associate with the percentage of muscle strength
nd physical activity, as well as with higher ESA requirements.
atients  and  methods
atients
his cross-sectional study comprised clinically stable male
atients with CKD attending the hemodialysis (HD) pro-
ram at Severo Ochoa Hospital, Leganes, Madrid, Spain. Only
atients who had been on HD for more  than three months
nd without hospital admissions in the month preceding the
nvestigation were invited to participate. Patients with phys-
cal limitations (amputation) and neurological impairment
ere not considered because of the difﬁculty in assessing
hysical activity. From 75 eligible patients, 57 patients met
he inclusion criteria and all accepted to participate. None
f the patients was receiving testosterone replacement ther-
py. All participants gave their written consent. The study
as approved by the Ethics Committee of the Severo Ochoa
ospital.
linical  data  including  co-morbidities
ach patient’s medical chart was reviewed to extract demo-
raphic and clinical data including comorbidities. Clinical
istory of cardiovascular disease (CVD) was deﬁned as car-
iac, cerebrovascular (including stroke) or peripheral vascular
isease. Mean arterial pressure (MAP) was deﬁned as [dias-
olic pressure + (systolic pressure − diastolic pressure)/3]. Dose
f erythropoietin-stimulating agents (ESAs) for each patient
as recorded as international units administered per week
U/week). Weekly doses of darbepoetin in micrograms were
onverted to international units of erythropoietin by multiply-
ng with a conversion factor of 200. The median ESA equivalent
ose was 6000 (0–15 300) U/week, which was normalized for
ody weight and for hemoglobin levels and presented as
/kg/mg/mL Hb/week in the following analyses.
aboratory  analysis
lood samples were collected before midweek dialysis session.
he plasma was separated within 30 min, and samples were
ept frozen at −70 ◦C if not analyzed immediately. Biochemical
arameters were determined by standard laboratory tech-
iques at the Biochemical Department of the Severo Ochoa
ospital. Interleukin-6 (IL-6) concentration was assessed on
lasma lithium heparin by multiplexing in a Bioplex system
X-MAP technology, BioRad, Madrid, Spain) using commercial
its (R&D Systems Europe, Ltd, UK). The concentration was
alculated by interpolation from the calibration performed
ith the corresponding recombinant proteins provided byPlease cite this article in press as: Cobo G, et al. Hypogonadism associated w
in men undergoing haemodialysis. Nefrologia. 2016. http://dx.doi.org/10.1
he kit. Total testosterone was assessed in serum with a
hemiluminescence assay (Advia-Centaur, Siemens) that has
ensitivity, speciﬁcity, precision and linearity according to
he requirements for usage in clinical practice. The normal x(x  x):xxx–xxx 3
reference range established by our laboratory for the male
population is 241–827 ng/dL.
Body  composition  assessment
Dry weight (based on clinical approach) in kilograms and
height in meters of each participant was recorded. Body
mass index (BMI) was calculated dividing weight in kilo-
grams by height in square meters (kg/m2). Body composition
was assessed by bioimpedance (Body Composition Moni-
tor, Fresenius Medical Care, Bad Homburg, Germany). The
measurement was performed immediately before the sec-
ond dialysis session of the week. Lean body mass (LBM) and
fat body mass (FBM) were expressed as percentages. Total
body water (TBW), extracellular water (ECW), intracellular
water (ICW) and the relation ECW/ICW were collected. Other
parameters obtained were body cell mass (BCM) in kg and an
estimated index of over-hydration (OH) in liters.
Physical  activity  measurement
Physical activity (PA) was measured by a Geonaute-onstep-
400® pedometer. Each patient was requested to wear the
device for six consecutive days (two HD days, two HD-free
midweek days, and two HD-free weekend days). Informa-
tion on PA was obtained from the device memory.  The data
were recorded as number of steps per day. We  used the
pedometer-determined PA classiﬁcation for healthy adults12
as a benchmark of PA degree. This classiﬁcation considered
that more  than 10 000 steps per day is the goal for an active
life13 and participants with PA recorded below 5000 steps/day
are considered sedentary.14
Statistical  analysis
All statistical analyses were performed using SPSS version 12
(SPSS Inc., Chicago, IL, USA). Data are expressed as mean ± SD
or median (range of 10th to 90th percentile) or percentage,
as appropriate. Statistical signiﬁcance was set at the level of
p < 0.05.
Comparisons between two groups were assessed with the
Kruskal–Wallis test for continuous variables and a 2 test for
nominal variables. Univariate analysis was performed using
Spearman correlation. Different multivariate linear regression
analyses were performed to test the independence of the asso-
ciation between testosterone and the three main dependent
variables: ESA dose, percentage of lean body mass and physical
activity (number of steps/day). All models were adjusted for a
priori decided biological confounders. Because bioimpedance
measurement was performed before the dialysis session,
LBM% may have been overestimated due to overhydration. As
a sensitivity analysis we tested further including OH in the
studied multivariate regression models. Since the variable ESAith muscle atrophy, physical inactivity and ESA hyporesponsiveness
016/j.nefro.2016.04.009
dose had a non-normal distribution, the Loge of the variable
was calculated and used in the multivariate analysis. Data are
presented as standardized coefﬁcient (ˇ) and standard error
(SE).
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Table 1 – General characteristics of 57 prevalent male HD patients and stratiﬁed according to the presence of




Testosterone < 241 ng/dL
n = 20
Normal
Testosterone > 241 ng/dL
n = 37
p-value
Age, years 65 (49–80) 72 (52–84) 63 (48–78) 0.03
BMI, kg/m2 25 (20–29) 25 (21–30) 24 (19–29) 0.2
MAP, mmHg 91 (76–109) 87 (73–99) 96 (78–113) 0.02
Diabetes, n (%) 22 (39%) 8 (40%) 14 (38%) 0.9
Cardiovascular disease, n (%) 36 (63%) 15 (75%) 21 (57%) 0.2
Vintage, months 30 (7–183) 29 (7–152) 30 (4–199) 0.7
Creatinine, mg/dL 8.0 (5.2–11.5) 7.9 (5.2–9.8) 8.1 (5.2–12.2) 0.4
Albumin, g/dL 4.0 (3.6–4.3) 3.9 (3.3–4.3) 4.0 (3.7–4.3) 0.3
Hemoglobin, g/dL 12.4 (11.2–13.9) 12.2 (11.2–13.9) 12.4 (11.2–13.9) 0.4
ESA dose, UI/kg/mg/dL/weeka 7.1 (0–17.3) 10.6 (4.3–36.6) 4.0 (0–15.5) <0.01
IL-6, pg/mL 3.6 (1.5–13.3) 4.7 (1.5–27.9) 3.3 (1.2–10.9) 0.05
TBW (L) 32 (28–44) 33 (26–47) 32 (28–44) 0.9
ECW/ICW 0.93 (0.82–1.15) 0.95 (0.83–1.18) 0.92 (0.77–1.07) 0.07
LBM (%) 48 (35–61) 45 (31–54) 48 (39–65) 0.04
FBM (%) 37 (27–46) 39 (31–48) 36 (25–43) 0.04
BCM (kg) 17.1 (10.7–27.2) 16.2 (9.5–27.9) 17.6 (11.2–27.4) 0.3
BMI: body mass index, MAP: mean arterial pressure, TBW: total body water, ECW:  extracellular water, ICW: intracellular water, LBM lean body
eightmass, FBM: fat body mass, BCM: body cell mass.
a ESA (erythropoiesis-stimulating agent) normalized by kg of body w
Results
Baseline  characteristics
Among the 57 patients included, the median age was
65 years (49–80) with a median dialysis vintage time of 30
(7–183) months. Twenty-two (39%) patients were diabetics
and 36 (66%) patients had a history of cardiovascular dis-
ease (CVD). Mean arterial pressure (MAP) at inclusion was 91
(76–109) mmHg. The median body mass index (BMI) was 25
(20–29) kg/m2.
Testosterone  levels  and  clinical  and  laboratory  data
The mean testosterone level was 321 ± 146 ng/dL. TwentyPlease cite this article in press as: Cobo G, et al. Hypogonadism associated w
in men undergoing haemodialysis. Nefrologia. 2016. http://dx.doi.org/10.1
patients (35%) had a testosterone concentration below the
normal range established in our laboratory and were clas-
siﬁed as having hypogonadism. The general characteristics
of all patients, and when placed in two groups according to
Table 2 – Univariate y linear regression multivariate models for
hemoglobin level (loge, UI/kg/week) (R2 0.27).
Variable Univariate 
Rho p v
Testosterone, ng/dL −0.30 0.
Age, years 0.30 0.
BMI, kg/m2 −0.18 0.
CVD (presence) 0.31 0.
Diabetes (presence) 0.07 0.
Albumin, g/dL −0.29 0.
Ferritin, ng/mL 0.09 0.
IL-6, pg/mL 0.27 0.
BMI: body mass index, CVD: cardiovascular disease. and by Hb level.
testosterone levels, are summarized in Table 1. Patients in the
hypogonadism group were older and had lower MAP, higher
IL-6, lower LBM and higher FBM. Other variables did not differ.
Testosterone  and  ESA  dose
The required weekly dose of EPO (normalized by weight and by
hemoglobin levels) was signiﬁcantly higher in the group with
lower testosterone levels (Table 1). This negative association
was also observed after adjustment for potential confounders
in a multivariable regression analysis (Table 2). Additional
adjustment for OH or dialysis vintage did not alter the results
(sensitivity analysis not shown).
Testosterone,  lean  body  mass  and  physical  activityith muscle atrophy, physical inactivity and ESA hyporesponsiveness
016/j.nefro.2016.04.009
In uni- and multivariate analysis, testosterone positively cor-
related with the percentage of LBM (Table 3). Additional
adjustment for dialysis vintage and OH did not alter the results
 weekly ESA dose normalized by weight and by
Multivariate analysis
alue  ˇ (SE) p value
04 −0.37 (0.001) 0.012
04 0.09 (0.01) 0.6
2 −0.24 (0.03) 0.08
03 0.08 (0.25) 0.6
7 −0.007 (0.21) 0.9
05 −0.24 (0.38) 0.09
6 −0.05 (0.001) 0.7
09 −0.13 (0.006) 0.3
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Table 3 – Linear regression model for lean body mass (percentage) and physical activity (number of steps/day).
Lean Body Mass (%) Physical Activity (Steps/day)
Univariate Multivariate analysis Univariate Multivariate analysis
Variable Rho  (p value) Adjusted Model 1
(R2 0.26, p=0.02)




Beta (p value) Beta (p value) Beta (p value)
Testosterone, ng/dl 0.29 (0.03) 0.33 (0.03) 0.26 (0.07) 0.33 (0.03) 0.22 (0.1)
Age, years −0.33 (0.02) −0.32 (0.04) −0.44 (0.002) −0.30 (0.04) −0.19 (0.2)
CVD (presence) −0.23 (0.09) 0.04 (0.8) −0.49(<0.001) −0.23 (0.09) −0.26 (0.04)
Diabetes (presence) 0.01 (0.9) −0.15 (0.3) −0.22 (0.14) −0.32 (0.02) −0.27 (0.04)
IL-6, pg/mL −0.38 (0.01) 0.13 (0.4) −0.32 (0.03) 0.17 (0.2) 0.13 (0.3)
LBM, % – – 0.59 (<0.001) – 0.34 (0.01)





































tdata are not shown). The average PA registered in the group
ith normal testosterone levels was 4291 ± 3225 steps/day
ompared to an average of 2753 ± 1784 (p = 0.04) in the group of
atients with hypogonadism. In multivariate regression mod-
ls considering confounders, testosterone levels remained
ositively associated to physical activity (Table 3, physical
ctivity adjusted model 1). However, when the percentage
f lean body mass was further included in the model (pre-
umed within the causal pathway), the association between
estosterone and physical activity ceased to be statistically sig-
iﬁcant, reducing the regression coefﬁcient of the association
ˇ) by approximately 30% (from 0.33 to 0.22) (Table 3, Physi-
al activity adjusted model 2). No changes in the model were
ound when we  additionally adjusted for dialysis vintage or
H (data not shown).
iscussion
his study shows that hypogonadism is rather common
mong men  undergoing HD and that, independently of age
nd other potential confounders, lower levels of endogenous
estosterone associate with higher doses of ESA, lower lean
ody mass and poorer physical activity.
The observed prevalence of hypogonadism among male
ialysis patients in our study (35% prevalence) is in line with
ecent reports,15,16 although larger dialysis cohorts document
p to 70% of their population to present with testosterone
eﬁcient levels.4,17 Inconsistencies in this information may
e affected by different inclusion criteria, age-ranges, differ-
nt cut-off points for hypogonadism and overall, differences
n clinical practice between countries.
Recently, low testosterone levels have been associated
ith lower levels of hemoglobin in ESA-naïve CKD patients
nd with higher ESA dosages in hemodialysis patients.18
hese data are now corroborated by the ﬁndings of our
tudy, where the prescribed dose for ESA was negatively
ssociated with serum testosterone levels. Testosterone isPlease cite this article in press as: Cobo G, et al. Hypogonadism associated w
in men undergoing haemodialysis. Nefrologia. 2016. http://dx.doi.org/10.1
nown to stimulate erythropoiesis through the production of
ematopoietic growth factors19 and through the improvement
f iron bioavailability via the hepcidin pathway.11 Considering
hat male hypogonadism may represent a contributing factorto renal anemia, restoration of this deﬁciency could potentially
be of value in the treatment of anemia.20–22
One of the most important actions of testosterone regards
its effect on body composition and metabolism. In our study,
we observed an independent direct association between
testosterone levels and muscle mass, which agrees with
community studies23,24 and expands to hemodialysis our pre-
vious observation in non-dialyzed men  with CKD stages 3–5.9
Testosterone increases muscle mass by multiple mechanisms;
including, differentiation of pluripotent stem cells toward the
myogenic lineage, as well as, stimulation of muscle protein
synthesis and inhibition of muscle protein degradation.7 A
novel ﬁnding in our report is the, perhaps expected, positive
and independent association between endogenous testos-
terone levels and physical activity as determined by number
of steps per day. Because the relationship between physi-
cal activity and testosterone levels ceased to be signiﬁcant
when muscle mass was included in the model (adjustment
in the causal pathway), it would seem congruent to spec-
ulate that this association appears to be explained by the
association between testosterone and muscle mass status.
It is not well known whether testosterone supplementation
affects muscle function over and above its effects on muscle
mass. Some interventions have tested the effects of supra-
physiological dosages of testosterone supplementation in HD
patients (both men  and women) with normal or unknown
testosterone levels, and described muscle growth effects.25,26
The study of Johanssen et al., however, did not see any mea-
surable improvement in physical performance coupled to this
anabolism. The intervention period, however (3 months) may
have been too short to discern this. Nevertheless, no study
has yet addressed the impact that restoration of hypogo-
nadism could have in improving or maintaining muscle mass
in this patient population subjected to a strong catabolic
environment.27
Our study has some limitations that should be pointed out,
starting by a reduced sample size and a cross-sectional design,
which does not allow establishing causal relationships. Theith muscle atrophy, physical inactivity and ESA hyporesponsiveness
016/j.nefro.2016.04.009
diagnosis of hypogonadism was performed based on a single
testosterone determination, and signs and symptoms of this
condition were not considered. However, because most hypog-
onadal symptoms coincide with those of uremia, reliance on
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testosterone levels in the setting of chronic diseases such as
CKD is indicated by some guidelines.28 The use of total rather
than free testosterone concentrations might result in under-
diagnosis because the concentration of sex-hormone binding
globulin increases with age. We collected samples before the
dialysis session, with some patients attending the afternoon
rounds. Because testosterone has a certain circadian variation,
this may have inﬂuenced our ﬁndings, however, toward the
null. On the other hand, performing the bioimpedance mea-
surement before the dialysis session could introduce a bias
on the value of LBM due to overhydration, in order to reduce
this possible bias the OH value was included in the different
models without ﬁnding any modiﬁcation on the results.
To conclude, we  show that hypogonadism is common
among our population of men  undergoing hemodialysis and
it is related to higher doses of ESA, reduced muscle mass
and poorer physical activity. Conceivably, these associations
reﬂect inadequate erythropoiesis and low muscle protein syn-
thesis due to low levels of circulating testosterone, while the
observed link between low testosterone levels and physical
inactivity is most likely explained by reduced muscle mass
due to hypogonadism. The results of the current study can
be of value to raise the awareness of male hypogonadism in
CKD and increase interest on the potential of treating this
endocrine deﬁciency. Although pharmacokinetics of testos-
terone administration seem unaffected in dialysis patients29
and we  are proposing restoration of clinical deﬁciencies rather
than supraphysiological administration, safety of this therapy
should not be taken for granted and needs to be conﬁrmed by
randomized controlled trials.
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